Boyle, JG, et al., Clinical Science (2018) 132 1699–1709
Publications
| Title | Venue | Type | Date |
| ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice | The 32nd European Congress On Obesity (ECO 2025) | Oral | 5/2025 |
| ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study | The 32nd European Congress On Obesity (ECO 2025) | Guided poster | 5/2025 |
| ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study | The American Diabetes Association's 85th Scientific Sessions (ADA 2025) | Poster | 6/2025 |
| ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model | The American Diabetes Association's 85th Scientific Sessions (ADA 2025) | Poster | 6/2025 |
© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号
浙ICP备11050387号-1
